In patients with cirrhosis, dehydration induced by diuretics is a common precipitant of hepatic encephalopathy (HE), which may respond to volume expansion. The mechanism of HE in this situation is not fully understood. The present study evaluates the effect of plasma volume expansion on the severity of HE, plasma and urinary ammonia in patients with diuretic-induced HE. Fifteen patients with alcoholic cirrhosis and diuretic-induced HE of Grade 2 or more were enrolled. In eight patients, 4.5 % human albumin solution (HAS) was used for volume expansion and in seven patients colloid (Gelofusine ® ) was used. Significant improvement of HE Grade was observed at 24 h and was sustained at 72 h (P < 0.05) only in the group treated with HAS. There were similar and statistically significant reductions in plasma ammonia concentration, plasma renin activity and angiotensin II and an increase in mean arterial pressure, renal plasma flow and urinary ammonia excretion in both groups. Plasma malondialdehyde was elevated in both groups, but was reduced significantly only in the group treated with HAS. The findings of the present study show that plasma volume expansion results in significant reduction in plasma ammonia concentration, possibly through an increase in urinary ammonia excretion. This reduction in ammonia concentration translates into an improvement in mental state only in those patients treated with HAS in whom concomitant reduction in oxidative stress was observed. These data support the notion that other factors, such as oxidative stress, act as adjuncts to ammonia in the pathogenesis of diuretic-induced HE and suggest a possible role for albumin infusion in its treatment.
INTRODUCTION
In patients with cirrhosis, ammonia [throughout the text, ammonia is used to denote ammonia (NH 3 ) and ammonium (NH 4 + ) unless the two entities are specified separately] is thought to be central in the pathogenesis of hepatic encephalopathy (HE) [1, 2] . The organs that are thought to be primarily responsible for the homoeostasis of ammonia are the gut and liver [3] . Recent studies in patients with cirrhosis have indicated an important role for the muscle and kidneys in maintaining ammonia levels [4, 5] . The kidneys dispose of ammonia following its production from glutamine through secretion (proximal convoluted tubule), reabsorption and concentration through counter-current multiplication (ascending limb of the loop of Henle and medullary interstitium) and, finally, secretion into the collecting ducts [6] . In the physiological state, most of the ammonia generated by the kidney is returned to the systemic circulation and a smaller proportion is excreted in the urine [7, 8] . This ratio is reversed in patients with cirrhosis, as the kidney becomes net ammonia 'disposer' [7, 8] . Acidosis promotes renal ammonia production and transport [9] . Chronic hyperkalaemia decreases ammonium production in the proximal tubule and whole kidney, inhibits absorption of NH 4 + , reduces medullary interstitial concentrations of NH 4 + and NH 3 , and decreases entry of NH 4 + and NH 3 into the medullary collecting duct [10, 11] . Other potent stimuli modulating ammonia synthesis, transport and excretion by the kidneys include renal blood flow, tubular cell pH and renal tubular lumen pH, luminal flow rate and angiotensin (ANG) II levels [12, 13] .
One of the common precipitating factors for the development of HE in patients with cirrhosis is diureticinduced dehydration. The mechanisms by which dehydration induces HE is unclear, but a contraction of the intravascular volume and its redistribution may reduce renal blood flow and, therefore, renal ammonia excretion. Renal ammonia excretion may be compromised further by activation of the renin-aldosteroneangiotensin axis, impacting upon renal ammonia excretion [12, 13] . Furthermore, dehydration induces oxidative stress, which may exacerbate the neuropsychological effects of hyperammonaemia [14] [15] [16] .
We have shown recently [17] that volume expansion in cirrhotic patients results in a reduction in plasma ammonia concentrations and an increase in urinary ammonia excretion. The aims of the present study were to determine the effect of volume expansion on the mental state, plasma ammonia and urinary ammonia excretion and a marker of oxidative stress in cirrhotic patients with diuretic-induced HE. We studied two groups of patients consecutively. The first group received volume expansion with 4.5 % human albumin solution (HAS; Baxter Bioscience, Newbury, Berks., U.K.) and the second group received colloid (Gelofusine ® ; Braun Medical Ltd, Aylesbury, Bucks., UK).
METHODS

Ethical approval
This prospective controlled study was conducted with informed and written assent from next-of-kin, with the approval of the Local Research Ethics Committee, and in accordance with the Declaration of Helsinki (1989) of the World Medical Association.
Patients
Fifteen patients with alcoholic liver disease (ten male and five female) and diuretic-induced HE of Grade 2 or more were enrolled. The patients had stable cirrhosis at their last outpatient follow-up and had been receiving standard diuretic therapy, which included spironolactone and frusemide. The first eight patients were treated with 4.5 % HAS (HAS group) for volume expansion and the subsequent seven patients received colloid (Gelofusine ® ; Colloid group). There were no significant differences in the patient characteristics between the HAS and Colloid groups (Table 1) . 
End point for volume expansion
The amount of fluid (HAS or Gelofusine ® ) administered was guided by the central venous pressure and urine output. The aim was to administer fluids intravenously until the central venous pressure was sustained at between 7-10 mmHg.
Inclusion criteria
Patients were included into this study if they had (i) HE of Grade 2 or higher (West Haven criteria) [18] , and (ii) HE was precipitated by dehydration (diuretic usage, oliguria, clinical evidence of dehydration and low central venous pressure).
Exclusion criteria
The patients were excluded if they had evidence of preadmission renal dysfunction (haematuria/proteinuria), cardiac impairment or focal neurological abnormalities, any symptoms or signs of alcohol withdrawal, hepatic or extrahepatic malignancy, presence of other known precipitants of HE, such as sepsis and gastrointestinal bleeding, use of sedative narcotics and constipation, and administration of any specific therapy for HE, such as lactulose or bowel enemas, prior to enrolment.
Study design and management
If the patients fulfilled the inclusion criteria, they were recruited into the study within 6 h of admission [median, 6 (range, 4. Requisite cultures (blood, urine and ascites) were taken at the bedside to establish the contribution of a possible 'occult' infection to the HE. All patients were fed through the nasogastric tube with an enteral meal providing 146 kJ/kg, 1 g/kg of protein, 100 mmol sodium, 40 mmol potassium and 60 ml/h of fluid. This meal was given over a period of 20 h and stopped 1 h prior to the study on day 1 (24 h) and day 3 (72 h). Each study period was of 3-h duration and all clinical, biochemical, neuropsychiatric and haemodynamic tests were repeated after 24 and 72 h of admission.
Neurological assessment
Neurological assessment was performed at the time of inclusion into the study and then at 24 and 72 h. Severity of HE was assessed using the West Haven criteria [18] . Tests of neuropsychiatric function (Trails B test; the test had to be completed within 420 s) and digital symbol substitution test (Dsst; the test score was the number of symbols correctly substituted in 90 s) were administered by a single investigator and scored as described previously [19, 20] .
Glomerular filtration rate (GFR) and renal plasma flow (RPF)
Primed continuous infusion of inulin (Inutest, 25 %; Laevosan-Gesellschaft, Linz, Austria) and para-amino hippuric acid (Merck Sharpe and Dohme, Sydney, Australia) were used as markers of GFR and RPF respectively [17, 21] .
Sampling and measurements
Plasma samples for circulating neurohormones [ANG II and plasma renin activity (PRA)] and plasma ammonia were taken. Blood was collected from a peripheral vein into pre-cooled tubes. Plasma was separated and the samples stored at − 70
• C for analysis at a later date. Urine was collected in a pre-cooled bottle which was maintained acidified with 2 ml of 6.0 M HCl in the urine collector, as described previously for measurement of ammonia, inulin and para-amino hippuric acid [17, 21, 22] . Inulin concentration was measured using spectrophotometry, and PAH was measured using HPLC [21, 22] .
PRA
The RIA for measurement of PRA was based on the principle that ANG I is generated by the action of renin on its substrate angiotensinogen. An in-house antibody for ANG I was used. The coefficient of variation for the assay was 5.2 %. The reference range for PRA was 1.6 + − 1.5 ng · h −1 · ml −1 [17, 21] .
ANG II
Samples of blood were obtained in ANG II inhibitor.
ANG II values were measured by RIA with an in-house rabbit antibody R6B4. The coefficient of variation for the assay was 3.2 %. The reference range for ANG II was 3.2 + − 1 pg/ml [17, 21] .
Plasma and urinary ammonia
Samples for ammonia estimation were kept on ice during processing. Ammonia was measured using standard enzymic method, as described previously [22] . The coefficient of variation for all determinations was < 4 %.
Malondialdehyde (MDA)
MDA was determined using a modified TBARS (thiobarbituric acid reactive substances) assay as described previously [23] . Control values for our laboratory were 0.9 + − 0.2 µmol/l.
Calculations
Urinary sodium, urinary ammonia and urinary volume values were used to derive the following parameters as follows:
Urinary ammonia excretion (mmol/h) = urinary ammonia × urinary volume
Fractional excretion of ammonia (%) = (urinary ammonia excretion/filtered sodium load) × 100
Ammonia clearance (ml/min) = urinary ammonia excretion/plasma ammonia
Statistical analysis
All the data are expressed as means + − S.E.M. The significance of changes within the study group was tested using one-way ANOVA during each of the three periods of observation (T = 0, T = 24 h and T = 72 h). A post-hoc analysis was done assuming unequal variance, using the Dunnett's C test. Difference between groups was tested using two-way ANOVA. Relationship between variables was tested using linear regression. A P value < 0.05 was taken to be statistically significant. 
RESULTS
Systemic haemodynamics and electrolytes
Both groups of patients showed evidence of severe dehydration indicated by tachycardia, hypotension, low central venous pressure and poor urine output. They had elevated urea and creatinine, reduced serum sodium and potassium and showed evidence of mild metabolic acidosis. Volume resuscitation resulted in a significant and sustained increase in the central venous pressure in both groups. In the first 24 h, the target central venous pressure (7-10 mmHg) was attained and sustained with 2.5 + − 0.8 litre of HAS in the HAS group and 2.9 + − 1.2 litres of Gelofusine ® in the Colloid group (P = 0.19 between groups). In the following 48 h, a further 0.9 + − 0.2 litres of HAS was administered to the HAS group and 1.4 + − 0.6 litres of Gelofusine ® to the Colloid group to sustain the increase in central venous pressure. Volume resuscitation was associated with a significant and sustained increase in mean arterial pressure, serum sodium and potassium, a decrease in the heart rate and correction of the metabolic acidosis. Serum albumin increased significantly from 27.1 + − 3.2 g/litre at baseline to 30.1 + − 2.6 g/ litre at 24 h to 28.8 + − 2.5 (P < 0.05) at 72 h in the HAS group. There was an insignificant reduction in serum albumin in the Colloid group ( Table 2) .
Severity of HE
HE Grade
Both groups of patients had similar severity of HE at baseline. There was a significant improvement in the HE Grade in the patients in the HAS group at both 24 and 72 h (P < 0.01), which was not observed in the patients in the Colloid group (P = 0.21). In the HAS group, three patients had Grade 3 HE, which improved to Grade 2 in two patients and Grade 1 in one patient at 24 h, and further to Grade 1 in one patient at 72 h. One patient remained with Grade 2 HE at 72 h. Of the five patients with Grade 2 HE, improvement to Grade 1 occurred in four patients at 24 h and at 72 h in one patient (Figure 1A) . In the Colloid group, of the two patients with Grade 3 HE, improvement to Grade 2 HE occurred in one patient at 72 h. The other patient remained in Grade 3 HE. Of the five patients with Grade 2 HE, improvement to Grade 1 occurred in one patient at 24 h and at 72 h in one patient. The other three patients remained at Grade 2 HE ( Figure 1B ).
Figure 1 Change in the clinical Grade of HE following volume repletion in patients receiving HAS (A) and Colloid (B)
Time 0 refers to the time the patients were entered into the study.
Neuropsychological tests
At baseline, it was not possible to perform the neuropsychological tests in three patients in the HAS group and in two patients in the Colloid group, because of the severity of HE. In the remaining patients, the performance of the patients for Trails B test and Dsst was similar. There was a significantly greater improvement in the Trails B test and also in the Dsst in the HAS group compared with the Colloid group (P < 0.01 using twoway ANOVA; Figure 2 ).
Change in renal function tests, renal haemodynamics and circulating neurohormones
Volume resuscitation resulted in similar and significant increases in urine output at 24 and 72 h in both groups. The increase in urine output was possibly due to increased RPF and GFR, both of which increased similarly and significantly in both groups. This resulted in a significant and sustained reduction in serum urea and creatinine in both groups, which was not significantly different. PRA and ANG II decreased significantly following volume repletion in both groups at 24 and 72 h. The reduction was similar in the two groups. The increase in the RPF correlated with the decrease in ANG II (r = 0.61, P = 0.01), but not with that of PRA (r = 0.44, P = 0.07). Similarly, the increase in GFR correlated with the decrease in ANG II (r = 0.75, P = 0.002) and PRA (r = 0.89, P < 0.001).
Plasma and urinary ammonia
At baseline, plasma ammonia concentration was high in both groups of patients and not significantly different from each other. With volume repletion, plasma ammonia was reduced significantly in both groups. This reduction in plasma ammonia was observed at 24 h, but sustained at 72 h, and was similar in both groups, which was associated with significant increases in urinary ammonia excretion and ammonia ( Table 2 ). The decrease in plasma ammonia levels correlated with the increase in urinary ammonia excretion (r = 0.97, P = 0.001). The change in plasma ammonia levels also correlated with the decrease in the levels of ANG II (r = 0.75, P = 0.002) and PRA (r = 0.79, P = 0.001). The change in urinary ammonia excretion correlated with the decrease in the levels of ANG II (r = 0.79, P = 0.001) and PRA (r = 0.82, P = 0.001). 
Plasma MDA
Plasma MDA levels were similar and elevated in both groups of patients. Following volume repletion, a significant reduction was noted only in the patients in the HAS group. This reduction was evident at 24 h and sustained at 72 h. No significant change was seen in the Colloid group (Figure 3) .
DISCUSSION
The present study is the first to explore the pathophysiological basis and the role of volume expansion in the treatment of patients with diuretic-induced HE. The result of this study highlights two important observations. Volume expansion resulted in significant and sustained reduction in plasma ammonia, which was associated with a significant increase in urinary ammonia excretion. Of significant interest was the observation that, although the improvement in systemic and renal haemodynamics and reduction in plasma ammonia were similar in the patients treated with HAS and Gelofusine ® , the improvement in HE was significantly more marked in the patients treated with HAS. The significantly greater reduction in MDA levels in patients treated with HAS points to the role of oxidative stress as an important adjunct to ammonia in the pathogenesis of diureticinduced HE. Diuretic-induced dehydration is a common precipitating factor for HE [24, 25] . The present study was conceived following our initial observation [17] that volume expansion with saline in patients with wellcompensated cirrhosis resulted in a decrease in plasma ammonia and an increase in urinary excretion of ammonia. In keeping with our previous observation [17] , volume repletion resulted in an increase in urinary ammonia excretion with consequent decrease in plasma ammonia levels. It is likely that the change in ammonia homoeostasis following volume expansion is probably due to an increase in luminal flow rate mediated by improved renal perfusion [26] , the cessation of diuretic therapy [6] , which is known to inhibit the transporters involved in the excretion of ammonia, and/or a reduction in renal ammoniagenesis mediated by a decrease in ANG II, which is an important modulator of the ammonia that is synthesized by the proximal tubule [11, [27] [28] [29] [30] [31] . In the present study, the significant correlation between a decrease in ANG II and plasma ammonia level on one hand and an increase in urinary ammonia excretion on the other supports this hypothesis, but does not prove unequivocally a cause-effect relationship.
The most important result of the present study was the observation that there was a significantly greater improvement in HE in patients treated with HAS compared with those treated with Gelofusine ® , despite a similar reduction in the plasma ammonia concentrations. This implies that the mechanism by which albumin infusion resulted in an improvement in HE is likely to be more than that produced by volume expansion alone. Human albumin is a 66 kDa molecule, constituting 50 % of the plasma proteins in healthy individuals. It has been used essentially as a plasma volume expander in the treatment of liver disease [32] [33] [34] . Although albumin infusion was associated with significant increases in the concentration of albumin, the increment was modest. This may reflect the fact that albumin is distributed very widely in the body and the relatively large volume of distribution in cirrhotic patients due to the concomitant ascites. Albumin has the ability to bind to a range of different molecules and act as a scavenger. It has a strong negative charge and binds reversibly to both cations and anions. These include a large number of metabolites, including fatty acids, bilirubin, bile salts, amino acids and nitric oxide. It is also the major extracellular source of reduced sulphydryl groups. These scavenge reactive oxygen and nitrogen species, especially superoxide, hydroxyl and peroxynitrite radicals. Albumin can also limit the production of these reactive species by binding free Cu 2+ , which is known to be important in accelerating the production of free radicals [32] [33] [34] . Interestingly, albumin administration in sepsis patients led to significantly increased levels of both plasma albumin and total plasma thiols [35] . Albumin may thus influence the redox balance and reduce oxidative stress [33, 34] . In keeping with this hypothesis, we were able to show a significant reduction in MDA levels, which is a well-recognized marker of oxidative stress. This reduction in MDA was not observed in the patients in the Colloid group. It is interesting to note that both groups of patients had markedly increased MDA levels at baseline, which may either reflect the effect of dehydration and/or severe cirrhosis, as increased oxidative stress is well-described in both situations. The results of our present study point to an important role of factors that act in concert with ammonia in the pathogenesis of diuretic-induced HE [14] [15] [16] . Clearly, these factors are likely to have an important albuminbinding component and, as we have shown in the present study, one such factor may be reactive oxygen species. There is emerging evidence suggesting that oxidative stress plays an important role in the development of HE [36] [37] [38] [39] , possibly by causing mitochondrial damage, including oxidation of membrane phospholipids and various enzymes involved in energy metabolism [39] [40] [41] [42] . Alternatively, the effects of albumin infusion may be through its effects on cerebral blood flow. Several studies have suggested that, in patients with cirrhosis, there is a redistribution of cerebral blood flow, particularly in the frontal cortex [43, 44] . Ginsberg and co-workers [45] have shown that albumin infusion can increase cerebral blood flow. Another possible explanation, which is more difficult to substantiate, is that gelatin infusion may, in some ill-defined manner, have interfered with recovery from HE. In future studies, control arms should include other fluids such as saline.
Our data question the role of conventional ammonialowering strategies, such as lactulose, non-absorbable antibiotics and bowel enemas, in the treatment of diuretic-induced HE. Simple intervention with fluid therapy results in a significant and substantial reduction in plasma ammonia concentration without any conventional ammonia-lowering strategy by simply targeting the kidneys, supporting our recent studies suggesting that the kidneys are important in ammonia homoeostasis [4, 15, 17] .
The use of albumin infusion in critically ill patients is a subject of considerable debate following a recently published meta-analysis [46] , suggesting poor outcome of critically-ill patients that were treated with albumin compared with other colloids. This meta-analysis has been criticized and the issue of the use of albumin as a volume expander in critically ill patients is being explored in controlled clinical trials [47] [48] [49] . In patients with liver disease, the use of albumin infusion as a volume expander has been studied in considerable detail. Studies [50, 51] have shown that albumin infusion following paracentesis is associated with a lower incidence of renal dysfunction compared with other colloids [32] . In patients with spontaneous bacterial peritonitis, the addition of albumin infusion to antibiotics improves survival compared with antibiotics alone [50] . In patients with hepatorenal syndrome, the addition of albumin infusion to the vasoconstrictor terlipressin improves survival compared with terlipressin [51] . These data emphasize both the safety and also the efficacy of albumin in cirrhotic patients.
The present study was terminated 72 h after entry into study, because it was designed to look at the pathophysiological mechanisms. This study can be criticized because of its non-randomized design. The patients in the HAS group were studied first and we were surprised at the rapid improvement in the severity of HE. The patients were recruited into the Colloid group to clarify whether the effects of HAS were due to volume expansion alone or to a non-oncotic property of albumin. Nevertheless, we believe the results are important and robust given that both groups of patients were well-matched for the severity of the underlying liver disease and HE, the degree of dehydration, their response to volume expansion, the reduction in circulating ammonia levels with volume expansion and the increase in urinary ammonia excretion.
In conclusion, the findings of our present study suggest that volume expansion in patients with diuretic-induced HE results in a significant reduction in plasma ammonia levels due to increased renal ammonia excretion. The significantly greater improvement in the severity of HE in the HAS group compared with the Gelofusine ® group indicates either a positive effect of albumin or a negative effect of Gelofusine ® on the mental state. The association of the greater improvement in the severity of HE in the HAS group with the greater reduction in a marker of oxidative stress supports the notion that protein-bound substances, such as reactive oxygen species, are important adjuncts to ammonia in the pathogenesis of diureticinduced HE and a possible role for HAS as the preferred volume expander in the treatment of such patients. These data advocate the need for a suitably powered randomized controlled clinical trial, using albumin infusion as an adjunct to conventional ammonia-lowering strategies in HE.
